Safety of rituximab therapy during the first trimester of pregnancy: a case history

被引：97

作者：

Kimby, E

Sverrisdottir, A

Elinder, G

机构：

[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, S-14186 Stockholm, Sweden

[2] Huddinge Univ Hosp, Karolinska Inst, Dept Oncol, S-14186 Stockholm, Sweden

[3] Huddinge Univ Hosp, Karolinska Inst, Dept Pediat, S-14186 Stockholm, Sweden

[4] Soder Sjukhuset, Stockholm, Sweden

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2004年 / 72卷 / 04期

关键词：

rituximab; pregnancy; first trimester; safety; follicular lymphoma;

D O I：

10.1111/j.1600-0609.2004.00214.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The optimal treatment of non-Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.

引用

页码：292 / 295

页数：4

共 14 条

[1] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[2]

Coiffier B, 1998, BLOOD, V92, P1927

[3] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[4] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[5]

DOLL DC, 1996, CHEMOTHERAPY SOURCE, P803

[6]

Gililland J, 1983, Obstet Gynecol Surv, V38, P6

[7]

Grillo-López AJ, 1999, SEMIN ONCOL, V26, P66

[8] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma [J].

Hainsworth, JD ;

Litchy, S ;

Burris, HA ;

Scullin, DC ;

Corso, SW ;

Yardley, DA ;

Morrissey, L ;

Greco, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4261-4267

[9]

Herold M, 2001, J CLIN ONCOL, V19, P3439

[10]

Kimby E, 2000, BLOOD, V96, p577A

← 1 2 →